Licensing status

Publication and contact information

Endocrine/metabolic disease

Metabolic syndrome; obesity

Lacto-N-fucopentaose III (LNFPIII)

In vitro and mouse studies suggest LNFPIII could help treat metabolic diseases. In macrophages, LNFPIII led to greater expression of anti-inflammatory IL-10 than vehicle. In mice with high-fat diet-induced obesity and metabolic syndrome, LNFPIII prevented hepatic steatosis and increased glucose tolerance and insulin sensitivity compared with vehicle. Next steps include improving the delivery method for the glycan and determining long-term effects.

SciBX 5(44); doi:10.1038/scibx.2012.1159
Published online Nov. 8, 2012

Patent Cooperation Treaty patent application filed; currently under option with an undisclosed company; unavailable for licensing

Bhargava, P. et al. Nat. Med.;
published online Oct. 28, 2012;
Contact: Chih-Hao Lee,
Harvard School of Public Health, Boston, Mass.
Contact: Donald A. Harn,
The University of Georgia, Athens, Ga.